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reductions cn the composite endpoint of death, repeat MI. ischemic target vessel revas- 
cularization (TVR), and disabling stroke (3.0% vs. 1.3%, p=O.Ol), largely due to a 
decrease in ischemic TVR (2.4% vs. 0.6%, p=O.O025). Abciximab also reduced early 
subacute thrombosis (1 .O% vs. O.l%, p=O.O06). Among 1703 pts in the U.S., mean times 
of hospital D/C in abcx and non-abcx treated pts were 4.9 + 2.7 days vs. 5.4+ 3.5 days 
respectively, p<O.OOl, and total mean in-hospital costs for the 2 groups were $13,413 
(abcx) vs. $13,000 (no abcx), p=O.13. In the first 7 days following hospital D/C, there 
were no significant differences relative to abcx treatment regarding the composite end- 
point (0.8% vs. 0.3%, p=NS) or its individual elements, nor were differences in major or 
minor bleeding observed. 
Conclusions- Adjunctive abciximab therapy during primary PCI is associated with 
reduced early adverse ischemic outcomes that may facilitate early hospital D/C and 
effect cost sawngs. However, standard times to D/C after primary PCI are now so short 
that efforts to further accelerate DIG with abciximab were for the most part not feasible, 
and cost savings were not realized. 
9:oo a.m. 
871-3 Duration of Cardiopulmonary Bypass and Risk of 
Perioperative Stroke in Coronary Artery Bypass 
Surgery Operations 
Ronald M. Weintraut$ Donald S. Likosky, Cathy S. Ross, Bruce J. Leavitt, Charles A. 
Marnn, David J. Malenka, Louis R. Caplan, Yvon R. Baribeau. Dawd C. Charlesworth, 
Felix Hernandez, Gerald T. O’Connor, Beth Israel Deaconess Medical Center, Boston, 
MA, Northern New England Cardiovascular Disease Study Group, Lebanon, NH 
Background:We previously ldenttfied patient and disease characteristics associated 
with risk of stroke following isolated CABG We hypothesized that duration of cardiopul- 
monary bypass (CPB) is an independent risk factor for stroke. 
Methods We collected data prospectively from 29,406 consecutive patients undergoing 
CABG with CPB between 1992 2000. Stroke was defined as a new focal neurological 
deficit lasting >24 hours. Patients were divided into quartiles by duration of CPB. We 
excluded patients requiring return to CPB and CPB ~30 mln and >=230 min. Direct stan- 
dardization was used to adjust for pre-operative risk factors. 
Results There were 460 (1.56%) strokes. Risk of stroke was twice as great (2.3% vs. 
1 .O%) in the highest quartile than in the lowest (ptrendc 0.001). This increased risk per- 
sisted after adjusting for pre-operative risk factors. 
Conclusion: Increasing duration of CPB was significantly associated with risk of stroke, 
independent of pre-operative risk factors. Possible mechanisms include damage to blood 
elements, increased embolic burden, and difficulty in separation from CPB. 
Table 1: Crude vs. Adjusted Rates of Stroke by Quartile of Cardiopulmonary 
Bypass Duration 
Rates of Strokes 
Quartiles of Pumptime (min) Crude Adjusted” 
<70 1.03 1.13 
70-66 1.23 1.24 
67-106 1.60 1.50 
109-230 2.19 2.06 
*Adjusted for age, sex, diabetes, vascular disease, renal failure or creatinine ,2ms/dl, 
acuity, ejection fraction ~40% 
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871-4 Impact of Coronary Artery Bypass Graft Versus 
Percutaneous Coronary Intervention With Stent on 
Disease-Specific Functional Status in Diabetic and 
Nondiabetic Patients: Results From the SOS Trial 
Zefeng Zhang, Elizabeth M. Mahoney, Rod H. Stables, Jean Booth, Fiona Nugara, John 
A. Spertus, William S. Weintrauh, Emory University School of Medicine, Atlanta, GA 
Background. Previous results from the SOS trial showed a significant benefit of CABG vs 
PCI with Stent on Seattle Angina Questionnaire (SAQ) scores at 6 and 12 mo. Results 
from the BARI trial suggested that for patients (pts) with diabetes (DM), CABG yields 
superior Survival relative to PTCA. The influence of DM on SAQ scores as well as 
whether the relative benefit of CABG vs PCI on SAQ scores applies to DM and non-DM 
pts is not known. Methods. The SOS trial randomized 966 pts with multivessel disease 
from 11196 to 12/99 to CABG (74 DM and 426 non-DM) or PCI with stent (68 DM and 420 
non-DM). We examined the influence of DM on 3 SAQ domains: physlcal limitation (PL), 
angina frequency (AF), and quality of ltfe (QOL) at baseline. 6 and 12 mo. as well as 
whether the relative effect of CABG vs PCI on 6 and 12 mo SAQ scores varied bv DM 
status. SAQ scores range from 0 to 100; higher scores indicate better functioning. All 
analvses were adiusted for slaniflcant covariates. Results. For DM and Non-DM Dts. PL. 
AF and QOL improved significantly after both CABG and PCI at 6 and 12 mo. and CABG 
showed greater gains compared to PCI for most SAQ domains (Non-DM: pcO.01 for 6 
mo PL, AF and QOL. ~~0.02 for 1 yr PL, AF and p=O.O9 for lyr QOL; DM, p=O.O2 for 6 
mo AF, p=O.O9 for 6 mo PL, p>O.lO for other domains). No DM by treatment interaction 
for any SAQ domains was found. Conclusion. While pts with DM tended to have lower 
improvements in PL. CABG appears to confer the same benefits compared to PCI in DM 
and non-DM pts. 
Mean changes for 3 SAQ domams (p-value for DM*treatment mtrractmn) 
SAQ scales 
PL DM 
Non-DM 
AF DM 
Non-DM 
QOL DM 
Non-DM 
6mo 
CABG PCI p CABG 
16.6 10.5 0.55 13.9 
20.3 16.4 16.4 
35.4 27.1 0.66 34.7 
36.2 29.6 37.5 
29.6 26.5 0.65 33.7 
33.2 26.0 35.1 
1 Yr 
PCI p 
10.0 0.94 
14.7 
31.6 0.75 
33.4 
30.1 0.61 
32.5 
9:30 a.m. 
871-5 Lower Preprocedural Hemoglobin Level Is Associated 
With Increased Risk of In-Hospital Mortality Following 
Percutaneous Coronary Intervention 
Ronald S. McKechnie, Cecelia Montoye, Eva Kline-Rogers, Michael J O’Donnell, 
Anthony C. DeFranco, William L. Meengs. Richard McNamara, John G. McGinnity, Kirit 
P&l, David Share, Arthur Riba, Mauro Moscucci, Blue Cross Blue Shield of Michigan 
CardiovascularConsortium, University of Michigan Hospitals, Ann Arbor, Ml 
Background Recent studies have shown a relationship between anemia and in-hospital 
mortality in patients undergoing CABG and with acute myocardial infarction (AMI). The 
prognostic implication of anemia in patients undergoing percutaneous coronary intewen- 
tion (PCI) is unknown. We evaluated the relationship between pre-procedural hemoglo- 
bin (Hgb) level and PCI mortality in a quality controlled regional database. 
Methods: ClInical, procedural, and outcome data on 26,313 consecutwe PCI were pro- 
spectively collected in a consortium of 9 hospitals. Pre-procedure Hgb levels were avail- 
able for 93.3% of patients. Patients were divided into quintiles based on pre-procedural 
Hgb level (g/dl):Ql(6.6-12.3), Q2(12.3-13.5), Q3(13.5-14.4), Q4(14.4-15.4), Qs(l5.4. 
20.1). The primary endpoint was in-hospital mortality. 
Results The in-hospital mortality rate was significantly higher !n 01 when compared to 
other quintiles (Table), (OR 2.4,CI 2.0.3.0,p~O.OOOl). After adjustment for comorbidities, 
Ql remalned an independent predlctor of in-hospital mortality (adjusted OR 1.37,95% Cl 
1.1.1.7,p<O.O2). Analysis of patients undergoing PCI < 24 hours of AMI revealed a higher 
mortality rate I” 01 and Q2 when compared with Q3-05 (pcO.05) (Table). 
Conclusions: Lower pre-procedural Hgb levels are associated with higher in-hospital 
mortality following PCI, particularly in patients within 24 hours of AMI. Whether optimiza- 
tlon of Hgb levels prior to PCI may be of clinical benefit remains to be determined. 
Hgb quintile All PCI patients (n=24,554) PCI with AMI < 24hr (n=3,737) 
Ql 2.9% 11.5% 
Q2 1.6% 9.0% 
1 1% 
Q4 0.9% 4.8% 
05 1.1% 3.6% 
9:45 a.m. 
871-6 Hospital Percutaneous Coronary Intervention Volume 
and Patient Mortality: Is the ACC/AHA Volume Minimum 
Appropriate? 
Andrew J. Epstein Saif S. Rathore, Kevin G. Volpp, Harlan M. Krumholz, Yale University 
School Of Medicine, New Haven. CT, Universih/ of Pennsvlvania Wharton School of 
Bustness. Philadelphia. PA 
Background: To minimize mortality, current ACCIAHA guidelines recommend hospitals 
offering percutaneous coronary interventions (PCls) perform at least 400 PCls annually. 
The appropriateness of this threshold to contemporary practice is unknown. 
Methods: We used data from the Agency for Healthcare Research and Quality 1999 
Nationwide Inpatient Sample, an administrative database of all discharges from a ran- 
dom sample of US hospitals, to assess the association between hospital PCI volume and 
in-hospital mortality. The sample included all PCI recipients age 18 years or older from 
214 hospitals in 22 states (n=ll5,910). Hospitals were grouped by annual PCI volume: 
low (5-l 99, n=55), medium (200.399, n=46). high (400-999, n=60), and very high (21000. 
n=33). We examined the crude association between hospital PCI volume and in-hospital 
mortality using chi-square tests. Multivariate logistic regression with generalized estimat- 
ing equations was used to evaluate the independent association between PCI volume 
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and mortality adjusting for patient factors. 
Results: Most patients underwent PCI at high (n=49,429, 42.6%) or very high 
(n=48,517. 41.9%) volume hospitals; few patients were treated at low (n=4,355, 3.8%) or 
medium (n=l3,609, 11.7%) volume hospitals. Crude in-hospital mortality rates differed 
for patients treated at low and very high volume hospitals (2.82% vs. 1.41%, p<O.OOl), 
but were comparable among patients treated at medium and high volume hospitals 
(1.75% vs. 1.68%. p=O.56). The multivariate adjusted odds of in-hospital mortality were 
similar for patients treated in medium (odds ratio [OR] 0.95, 95% confidence interval [Cl] 
0.76-l .17), high (OR 1.00, referent), and very high volume hospitals (OR 0.96, 95% Cl 
0.83-l .lO). Patients treated at low volume hospitals were at increased risk of mortality 
(OR 1.37, 95% Cl 1.08-l .74). 
Conclusion: Although based on administrative data, our analysis found no evidence of 
higher in-hospital mortality among patients undergoing PCI at medium volume hospitals 
(ZOO-399 cases) compared with patients treated at hospitals with annual PCI volumes of 
400-999 cases. suggesting the ACC/AHA PCI hospital volume minimum may merit 
reevaluation. 
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885-l Patient, Hospital, Physician, and Market Correlates of 
One-Year Costs After Acute Myocardial Infarction in the 
Elderly 
Lawrence Liao, M. K. Bundorf, Kevin A. Schulman. David J. Whellan, Daniel B. Mark, 
James G. Jollis, Duke Clinical Research Institute, Durham, NC 
Background: Studies examining costs following myccardial infarction (Ml) have been 
limited by short follow-up, small sample sizes, restricted patient populations, or failure to 
include hospital (H), physician (P), or market (M) characteristics. In a national sample 
with extensive supplemental data, we sought to identify the factors associated with costs 
in the year following Ml. 
Methods: 84,373 elderly acute Ml patients (90% white, 49% female) in the Cooperative 
Cardiovascular Project were linked to Medicare Part A claims, AHA Hospital Surveys, the 
CMS directory of physician specialties, and the CMS Hospital Wage Index File. Medicare 
charges were converted to costs using institutional cost to charge ratios. Associations 
with admission episode and one-year log-transformed costs were assessed by ragres- 
sion analysis with robust standard errors. 
Results: Mean cost was $12,956 (median $6,633) for the admission episode and 
$19,597 (median $13,583) at one year. Patient characteristics only accounted for 11% of 
the admission and one-year cost variation. Patient variables most highly associated with 
one-year costs included anterior Ml ($1455 more), CHF (51858 more), and COPD 
($1894 more). Older age (age 2 80 years) was most strongly associated with lower costs 
($5693 less). After adding HPM variables, the models explained 22% of admission and 
17% of the one-year cost variation. After adding treatment and outcome variables, the 
models explained 55% of the admission and 59% of the one-year cost variation. The 
variables most highly associated with one-year costs were procedures including echo 
($4261 more), thrombolysis ($3856 more), catheterization (514,064 more), PCI ($8,264 
more), and CABG ($24,622 more). While patient death was associated with lower admis- 
sion episode costs, it was also associated with higher one-year costs. 
Conclusion: In models including patient, HPM, care, and outcomes data, cardiac proce- 
dures account for the largest share of admission and one-year health care cost variation. 
These data indicate that strategies focusing on appropriate procedure use have the 
greatest potential to produce important cost savings. 
IO:45 a.m 
885-2 Modeling the Cost-Effectiveness of Clopidogrel in 
Acute Coronary Syndromes Without ST-Segment 
Elevation in Sweden 
Peter Lindaren Bengt Jonsson. Institute of Environmental Medicine, Karollnska Institute, 
Stockholm, Sweden, Stockholm School of Economics, Stockholm, Sweden 
Background: The CURE trial showed a relative risk of 0.8 of suffering from stroke, myo- 
cardial infarction (Ml) or cardiovascular death in patients treated with Clopidogrel + ASA 
compared to ASA alone. The purpose of this study was to evaluate the cost-effective- 
ness in terms of cost per life year gained (LYG) of this treatment in Sweden. 
Methods: A Markov model with six states (at risk, first year with stroke, following years 
with stroke, first year with new MI, following years with new MI and death) was used. The 
risk of suffering stroke, Ml or cardiovascular death for patients hospitalized with unstable 
angina was calculated based on data from the Swedish inpatient and causes of death 
registers using logistic and W&bull regressions. Mortality was estimated using data from 
the same sources. Intervention was studied for a period of 12 months (maximum tollow- 
up in the trial), and the intervention costs and effect was annualized based on the 9- 
month average follow-up in the CURE trial. Costs (direct, indirect and costs in added 
years of life) due to different events were taken from published sources, while cost for the 
initial hospitalization was estimated based on data from the CURE trial. In the base-case, 
simulations were performed for a 64-year old cohort consisting of 61.3 % men (similar to 
that of the trial). LYG was used as the measure of effectiveness. Cost and effects were 
discounted at 3%. 
Results: The model predicts an incremental survival of 0.12 years and incremental direct 
costs of 149 US$ per patient. Including indirect costs and costs in added years of life the 
incremental cost IS 1,959 US$. The treatment is cost-saving if costs in added years of life 
are excluded. The incremental cost-effectiveness ratio is thus 1,290 US$/LYG or 15,199 
US$/LYG depending on perspective. Using the upper bound of the 95% Cl of the relative 
risk in the trial. the ratios are 4,942 US$/LYG and 20,382 US$/LYG. Older patients show 
more favorable ratios than younger ones when considering direct costs only, while the 
opposite is true when all costs are included. 
Conclusion: Clopidogrel + ASA compared to ASA alone in this indication shows a favor- 
able cost-effectiveness ratio compared with other cardiovascular therapies. 
ll:oo a.m. 
885-3 Effect of Gender According to Age on In-Hospital 
Mortality in Patients With Acute Myocardial Infarction in 
the ACC-National Cardiovascular Data Registry 
Sean C. Beinart. Viola Vaccarino, Jerome L. Abramson, Kathleen Hewitt, William S. 
Weintraub, on behalf of the American College of Cardiology National Cardiovascular 
Data Registry, Emory University. Atlanta, GA 
Background: Past studies evaluating the effect of gender on percutaneous coronary 
intervention (PCI) outcomes in patients with AMI have shown conflicting results. It has 
also been suggested that younger, but not older, women represent a high risk group for 
coronary interventions. 
Objective: To determine whether women have a greater risk for in-hospital mortality in 
younger, but not in older patients. 
Methods: The study population included 59,792 cases with AMI who underwent PCI in 
223 hospitals participating in the ACC-NCDR from l/l/98 to 9/30/2001. Logistic regres- 
sion models ware fit using over 30 demographic, clinical, and angiographic variables to 
assess the effect of female gender on risk adjusted in-hospital mortality. The interaction 
between age in lo-year increments and gender was assessed with the Breslow-Day test 
(unadjusted) and likelihood ratio test (adjusted). 
Results: 19,292 (32.3%) of the cases were women. Although the unadjusted relative risk 
ot death for females compared to males was higher in the younger than in the older 
patients, the excess risk for women at younger ages was explained by differences in 
comorbid diseases and clinical severity between younger men and women. Overall after 
multivariate adjustment women had a 32% higher mortality risk compared with men. 
Conclusions: Women undergoing PCI after AMI, overall, have a higher risk of In-hospi- 
tal mortality than men. The effect of gender does not vary across age after accounting for 
differences in clinical risk and comorbid illness. 
Effect of Gender on In-Hospital Mortality by Age Group 
Overa Age< Age Age Age Age Interacti 
II 50 50-59 60-69 70-79 >=80 on p 
Value 
Number of cases 59,742 11,214 15,517 14,345 12,861 5.805 
Unadjusted Odds 1.79 1.92 1.68 1.15 1.21 1.14 0.02 
Ratio (95% (1.64- (1.27- (1.31- (0.95. (1.05- (0.X- 
Confidence Interval) 1.94) 2.69) 2.15) 1.39) 1.40) 1.36) 
Adjusted Odds Ratio 1.32 1.23 1.55 1.16 1.34 1.36 ns 
(95% Confidence (1.19. (0.79. (1.18- (0.93. (1.14- (l.l- 
Interval) 1.46) 1.92) 2.02) 1.43) 1.58) 1.67) 
ii:15 a.m. 
885-4 Disparities in the Treatment of Acute Myocardial 
Infarction: Underutilization of Evidence-Based 
Therapies for Patients With Non-ST-Segment 
Myocardial Infarction 
Matthew T. Roe, Lori Parsons, Charles Pollack. John G. Canto, Hal V. Barron, Nathan 
Every, William Rogers, Eric D. Peterson, Duke Clinical Research Institute, Durham, NC 
Background: While multiple observational studies have characterized the use of ew- 
dew?-based therapies for patients with ST-segment elevation myocardial infarction 
(STEMI), the care of patients with non-ST-segment elevation Ml (NSTEMI) has not been 
as well-described. 
Methods: Treatments used for patients wth acute Ml from the National Registry of Myo- 
cardial Infarction (NRMI)-4 (June, 2OOQ - June, 2002) during the initial hospitalization 
were analyzed. Patients who were transferred-in from another hospital and those who 
were transferred-out were excluded. Acute (within 24 hours of presentation) and dis- 
charge care for “ideal’ patients without contraindlcations to the given therapies were 
compared for patients with STEMI vs. NSTEMI. 
Results: A total of 185,968 patients from 1,247 U.S. hospitals ware included in the anal- 
ysis. Approximately 71% of the patients presented with NSTEMI. 
Conclusions: Despite higher-risk clinical characteristics, patients with NSTEMI are 
treated less aggressively than patients with STEMI. However, evidence-based therapies 
are underused for all patients with acute Ml and in-hospital mortality rates are substan- 
tially higher than those seen in clinical trial populations. 
